Globally, Glaucoma is the second leading cause of blindness after cataract. In India, approximately 11 million people have lost their vision due to this incurable disease. Compliance is a major concern in treating Glaucoma as nearly 50% of patients admit non-continuous use of medications by 6 months after start of therapy. Multiple dosing limits patient’s adherence to the treatment and thereby, worsens the condition. Patients feel that the treatment of Glaucoma is inconvenient and interferes with their day-to-day life. Bausch+Lomb’s Travoflo is a convenient once-daily-dosing therapy for Glaucoma, which is aimed at improving patient compliance by reducing the number of interruptions and improving the overall outcome.
Clio Site Relaunch
Welcome to the New Clios.com: Celebrating Creativity 365 Days a YearRead More
The Most Awarded Silver and Bronze Clio Winners 2016Read More
2016 Innovation Gold Clio Winners
5 Campaigns Pushing the Boundaries of InnovationRead More
What Clio 2016’s Winning Work Says About the Future of AdvertisingRead More